Loading annual review details
Amcor plc (AMCR)FY2026 investor yearly review
Across FY2026, management emphasized disciplined integration of Berry, accelerating synergy capture, and portfolio optimization while navigating weaker volumes, extreme inflation, and working-capital timing. By Q4, they highlighted stabilization in price/cost and broad-based volume improvement, while guiding a tight transition period and calendar 2027 momentum.
Overall investor read
Execution-led year with cash-flow timing risk
Synergies and cost/productivity progressed steadily, while free cash flow was heavily influenced by working-capital timing tied to inflation volatility.
Primary financial signal
Revenue scaled, margins recovered, cash flow lagged
FY revenue and earnings rose meaningfully, gross margin reached 20.0%, but operating/FCF conversion data reflected severe cash timing pressure.
Primary call signal
From integration delivery to 2027 confidence
Q4 framed a move from largely integration-heavy work toward sustained growth initiatives and a deleveraging pathway tied to recoverable working capital.
Headline outcomes summarizing revenue growth, profitability, and cash/credit signals.
Revenue
Revenue surged alongside the Berry integration effect.
Gross margin
Gross margin ended the year at 20.0%.
Operating margin
Operating margin rose to 8.1% for FY2026.
Net income
Net income more than doubled versus the prior year.
Diluted EPS
EPS increased materially, consistent with management’s synergy focus.
Free cash flow
FCF was depressed versus the prior year baseline.
Net cash
Balance sheet showed net cash at fiscal year-end.
Current ratio
Current ratio data indicates high short-term liquidity.
Management’s narrative shifted from “first-quarter integration and cost synergies” to “inflation resilience and portfolio sharpening,” then to “calendar 2027 growth outperformance” as volume stabilized by Q4.
Integration execution
Across Q1–Q4, management described the Berry combination becoming a unified operating model, with synergy delivery moving from building blocks to exceeding expectations. Q3 quantified acceleration and an updated year-1 expectation above the initial target; Q4 reported Q4 synergy realized and full-year total.
Quarter-by-quarter materiality and tone for annual transcript themes.
Scroll horizontally to see more columns.
| Theme | Q1 | Q2 | Q3 | Q4 | Next monitor |
|---|---|---|---|---|---|
| Synergy delivery moved from building to exceeding targets | Positive Q1 synergies hit upper guidance; revenue pipeline built | Positive |
Synergy capture and portfolio focus improved earnings quality, while cash generation and volume volatility remained the core constraints.
Management described synergy delivery as repeatedly building and ultimately exceeding the initial year-1 target, with Q4 synergies realized and full-year totals above expectation.
Management indicated noncore businesses improved year-over-year by Q4 and that progress on sale agreements sharpened focus on higher-return core opportunities.
In Q4, management highlighted strong price pass-through of inflation and expectation that the price/cost relationship would remain stable through the transition period.
FY2026 narrative moved from first-quarter integration proof to mid-year synergy acceleration, then inflation-and-working-capital management, finishing with broad-based stabilization and transition guidance.
Earnings resilience vs. cash timing
Integration and cost discipline drove early EPS outperformance, then synergy acceleration and portfolio exits increasingly anchored the year as inflation mitigation and working-capital timing shaped cash.
Management highlighted first full quarter integration into a unified organization, with EPS above midpoint and synergy delivery toward the upper end. They also explained volume softness as more localized (e.g., Europe flexibles) and reassured guidance did not rely on demand improvement.
Read earnings transcriptManagement said Q2 financial performance matched expectations, while synergy benefits accelerated and strengthened the full-year confidence. They acknowledged a challenging noncore environment in Q2 (notably North American beverage dynamics), expecting improvement in later quarters as commercial terms improved.
Guidance comparisons are directional and largely limited to reported actuals; management provided multiple explicit EPS and free-cash-flow ranges during the year.
Adjusted EPS of $0.80 to $0.83 per share (reaffirmed); December-quarter EPS $0.16 to $0.18 incl. ~$50M–$55M synergies.; Free cash flow guidance $1.8B to $1.9B in FY’26 (not Q1).
Revenue $5.75B; Gross margin 19.6%; EPS $0.57; Other -$45M
Management reaffirmed full-year EPS and free-cash-flow targets in Q1; Q1 actual revenue/FCF were volatile, making quarter-level guidance matching incomplete.
FY adjusted EPS range updated to $4.0 to $4.15 per share (reflecting reverse stock split).; Reaffirmed free cash flow guidance $1.8B to $1.9B in FY’26.
Revenue $5.45B; Gross margin 16.4%; EPS $2.38; Other $2.15K
Q2 provided explicit full-year EPS and free-cash-flow ranges, but reported FY cash-flow measures in financial_context appear far below those targets, indicating a gap driven by timing factors management later described.
Key forward-looking monitoring points from management’s repeated frameworks: synergy conversion, working-capital recovery, and volume/mix resilience in focus categories.
The year’s earnings profile increasingly depended on synergy realization and pipeline ramp.
Track quarterly synergy realization and growth-synergy award ramp timing across segments.
Free cash flow timing was a recurring constraint and links directly to leverage and investment capacity.
Monitor management’s pacing to recover the ~$500M working-capital impact and working-capital KPI targets (inventory/DSO/DPO).
Capital allocation / portfolio
The year began with early divestiture agreements and continued emphasis that EPS/cash growth was largely self-help, then moved to concrete progress in Q3 with multiple additional sale agreements and Q4 with divestitures completed and noncore performance improving year-over-year.
Resilience / pricing power
In Q1 and Q2, management leaned on cost-out and productivity while affirming guidance without macro improvements. In Q3–Q4, they emphasized coordinated efforts to secure supply and use responsible pricing to mitigate rapid input-cost inflation, while working capital timing varied by environment.
Cash flow / leverage
Management repeatedly tied cash generation to working-capital management rather than operating failure. Q3 described holding more inventory and adjusting expectations for free cash flow, and Q4 linked the full-year cash shortfall to Middle East-related working-capital impacts in inventories and receivables.
Q2 synergy benefits accelerated; confidence in 2026 ramp
Positive Q3 synergies exceeded year-1 target; EPS guide raised |
Positive Q4 synergy realization brought FY totals 10% ahead |
| Track quarterly synergy realization vs. guidance, plus pipeline conversion to revenue synergies. |
| Portfolio optimization advanced with clearer noncore exit path | Positive Q1 sold two noncore businesses; more actions expected | Positive Q2 advanced noncore alternatives; North American beverage discussions continued | Positive Q3 added sale agreements; noncore performance improved | Positive Q4 reported divestitures completed; noncore execution improved | Monitor announced vs. closed divestitures and whether noncore EBIT margins normalize in back half. |
| Inflation resilience via supply continuity and pricing actions | Neutral Q1 emphasized self-help; guidance not dependent on demand | Mixed Middle East pressures eased for Q4; supply/pricing playbook emphasized | Positive Q4 price realization stable; supply continuity maintained | Watch management’s discussion of pass-through mechanisms, price realization, and any residual Middle East effects. |
| Cash flow timing driven by working capital and inventory decisions | Negative Q3 held more inventory; free cash flow guidance lowered | Negative Q4 attributed FCF shortfall to inventories/receivables impacts | Monitor working capital recovery targets, including DSOs/DSI movement and the pacing toward $500M return. |
| Focus categories kept volumes resilient as core held up | Positive Q1 focus categories outperformed; pet care resilient | Positive Q2 focus categories modestly outperformed; pet care standout | Positive Q3 focus categories were collectively flat despite volumes down | Positive Q4 focus categories in line; green shoots in pet/protein | Track focus-category volume performance and margin mix as the year transitions into calendar 2027. |
| Geographic volume pattern shifted from storm pressure to broad-based improvement | Mixed Q1 volumes down ~2% excluding noncore beverage; Europe weaker | Neutral Q2 volumes broadly consistent; emerging markets growth offset | Negative Q3 winter storms hit rigid production days and volumes | Positive Q4 volumes modestly grew; developed markets improved sequentially | Monitor sequential volume changes by region (North America, Europe, Asia/LatAm) and storm-related commentary. |
Across the year management cited strong customer receptiveness, pipeline growth, and examples of growth synergies from combined product portfolios translating into new awards.
Despite improved earnings, management lowered free cash flow expectations in Q3 due to inventory and working-capital timing, and in Q4 linked shortfall to Middle East-driven inventory/receivables impacts.
Management described softer volumes across parts of the year (including Europe challenges and Q3 winter storm impacts), then reported broad-based volume improvement in Q4 rather than sustained strength earlier.
In Q3–Q4 management stressed collaborative customer dialogue, pass-through mechanisms, and holding inventory to secure supply, implying cash and earnings sensitivity to input-cost dynamics.
Management characterized Q2 noncore EBIT margins as difficult due to volume headwinds and described expectations for normalization in the second half supported by improved commercial terms.
Scroll horizontally to see more columns.
| Quarter | Revenue | YoY revenue growth | Diluted EPS | Gross margin | Investor read |
|---|---|---|---|---|---|
| Q1Sep-25 | $5.75B | 13.0% | $0.57 | 19.6% | Synergy momentum and cost flexing supported EPS above midpoint while volumes stayed pressured, especially in Europe flexibles demand. |
| Q2Dec-25 | $5.45B | -5.2% | $0.38 | 16.4% | Synergies accelerated and core EBIT held up despite modestly down volumes; noncore weakness was expected to improve later. |
| Q3Mar-26 | $5.91B | 8.5% | $0.6 | 17.9% | Synergies accelerated and core outperformed mix, but working-capital actions (inventory holding) pressured free cash flow; Q4 outlook framed as contained. |
| Q4Jun-26 | $6.4B | 8.2% | $0.83 | 25.2% | Broad-based volume improvement and stable price realization supported resilient earnings as management guided the transition period tightly. |
Management framed the year-to-date as resilient in turbulent conditions, with synergy delivery reaching accelerating levels. At the same time, they guided lower free cash flow due to holding more inventory to protect supply continuity and mitigate inflation timing, while maintaining confidence in Q4 earnings impact.
Read earnings transcriptIn Q4, management reported modestly positive volume growth and emphasized coordinated supply and pricing actions to mitigate rapid inflation. Synergy capture exceeded initial year-1 expectations, but free cash flow was impacted by working-capital effects attributed to the Middle East conflict, leading to tight transition period guidance.
Read earnings transcriptFY adjusted EPS expected $3.98 to $4.03 per share; Q4 EPS growth implied ~20% YoY at midpoint.; FY free cash flow expected $1.5B to $1.6B (inventory/work-capital timing).
Revenue $5.91B; Gross margin 17.9%; EPS $0.6; Other $2.15K
Management adjusted the free-cash-flow range downward in Q3 due to holding inventory; later FY cash metrics suggest the gap widened beyond that updated expectation.
6 months ending Dec 31, 2026 adjusted EPS $1.80 to $1.90 per share.; Price/cost relationship expected stable through the transition period (no explicit FCF range).
Revenue $6.4B; Gross margin 25.2%; EPS $0.83; Other -$468M
Q4 guidance was communicated as a tight transition-period EPS band; quarter-level actuals align on profitability but cash realization remained constrained by working-capital timing.
Management repeatedly framed mitigation of inflation as dependent on pricing offsetting input-cost changes.
Watch commentary on price realization vs. raw material pass-through and stability of price/cost through the transition period.
The company’s core narrative relies on focus categories outperforming in modestly challenging demand environments.
Monitor volume trends in pet care, proteins, foodservice, and health care mix shift; compare core vs company volume.
Noncore portfolio optimization affects cash needs, earnings mix, and the credibility of sharpening the core story.
Track remaining noncore sale discussions/closures and whether noncore EBIT margins normalize in back half execution.
Dafinchi